The Insider: Meet the CEOs Webcast Replay

We were joined by the CEOs of exciting ASX-listed businesses, who gave valuable insight to their industries and companies future prospects.

  • (ASX: SP3) Spectur Limited – Dr Gerard Dyson
  • (ASX: PCK) PainChek Limited – Philip Daffas

Recorded on 6th July 2022 at 12pm (AEST).

Join the next The Insider: Meet the CEOs webcast

Speak to the Reach Markets team


Dr Gerard Dyson

Managing director - Spectur Limited (ASX: SP3)

Spectur makes communities in remote and unpowered areas safer by providing the only surveillance solution that can spot a problem, make a decision and take an action – without human assistance. Using artificial intelligence, Spectur’s platform can help stop theft, trespassing, illegal dumping or vandalism and protect communities from floods, bushfires, tsunamis, storms or shark attacks. Spectur has no direct competitors addressing these challenges, has grown to dominate its home market in WA and is trusted by institutions such as Optus, Surf Life Saving and the Department of Defence. Targeting an immediate $300 million-plus market opportunity, Spectur aims to replicate its success in WA and is expanding across Australia, New Zealand and select US states.

Philip Daffas

CEO - PainChek Limited (ASX: PCK)

PainChek is an Australian healthcare tech company and developer of the world’s first smart device-based pain assessment and monitoring application for infants and adults. The company’s SaaS AI platform is contracted to 126,000 patient beds across 1500 facilities globally, claiming a dominant 60% market share in Australia. In the year to March 2022, PainChek has shown consistent growth in customer revenue, contracted beds and subscriptions – demonstrated by its $3.2 million in ARR. The company is positioned to capture a near $1.3 billion global market opportunity spanning ANZ, Europe, the US, Canada, Japan and Singapore, leading up to FY24.

latest other webcasts

Felix Gold (ASX: FXG) Webcast Replay

Far East Gold (ASX: FEG) Webcast Replay

Prescient Therapeutics (ASX: PTX) Webcast Replay

Speak to the Reach Markets team

What is a 708 investor?

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement.